Trial reportJournal of veterinary internal medicine
Multicenter prospective trial of hypofractionated radiation treatment, toceranib, and prednisone for measurable canine mast cell tumors.
Trial report in Journal of veterinary internal medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.
- Tyrosine kinase inhibitors as an alternative treatment in canine mast cell tumor.Frontiers in veterinary science · 2023Pooled it
- c-Kit Mutation and Localization Status as Response Predictors in Mast Cell Tumors in Dogs Treated with Prednisone and Toceranib or Vinblastine.Journal of veterinary internal medicine · 2018Trial
- Anti-cancer effects ofOpen veterinary journal · 2024Article
- Investigation of Gastrointestinal Toxicities Associated with Concurrent Abdominal Radiation Therapy and the Tyrosine Kinase Inhibitor Sunitinib in a Mouse Model.International journal of molecular sciences · 2024Article
- Evaluation of Tumor Grade and Proliferation Indices before and after Short-Course Anti-Inflammatory Prednisone Therapy in Canine Cutaneous Mast Cell Tumors: A Pilot Study.Veterinary sciences · 2022Article
- Diagnosis, Prognosis and Treatment of Canine Cutaneous and Subcutaneous Mast Cell Tumors.Cells · 2022Review
- Modulation of mTOR signaling by radiation and rapamycin treatment in canine mast cell cancer cells.Canadian journal of veterinary research = Revue canadienne de recherche veterinaire · 2022Article
- Combination vinblastine and palladia for high-grade and metastatic mast cell tumors in dogs.The Canadian veterinary journal = La revue veterinaire canadienne · 2021Article
- Comparative oncology: The paradigmatic example of canine and human mast cell neoplasms.Veterinary and comparative oncology · 2019Review
- Combination vinblastine, prednisolone and toceranib phosphate for treatment of grade II and III mast cell tumours in dogs.Veterinary medicine and science · 2018Article
- Volumetric Modulated Arc (Radio) Therapy in Pets Treatment: The "La Cittadina Fondazione" Experience.Cancers · 2018Review
- Development of an in vitro model of acquired resistance to toceranib phosphate (Palladia®) in canine mast cell tumor.BMC veterinary research · 2014Article
- Canine mast cell tumors: diagnosis, treatment, and prognosis.Veterinary medicine (Auckland, N.Z.) · 2014Review
- Pulse-Administered Toceranib Phosphate Plus Lomustine for Treatment of Unresectable Mast Cell Tumors in Dogs.Journal of veterinary internal medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundMast cell tumors (MCT) are common cutaneous tumors in dogs and when not amenable to surgical excision can present a therapeutic challenge. New treatment protocols for unresectable MCT are needed. HYPOTHESIS: The combination of toceranib, prednisone, and hypofractionated radiation treatment (RT) will be well tolerated and efficacious. ANIMALS: Seventeen client-owned dogs with measurable MCT amenable to RT.
methodsProspective clinical trial. All dogs received prednisone, omeprazole, diphenhydramine, and toceranib. Toceranib was administered for 1 week before initiating RT, consisting of 24 Gy delivered in 3 or 4 fractions.
resultsOn an intent-to-treat basis, the overall response rate was 76.4%, with 58.8% of dogs achieving a complete response and 17.6% a partial response. The median time to best response was 32 days, and the median progression-free interval was 316 days. The overall median survival time was not reached with a median follow-up of 374 days. The most common toxicoses were gastrointestinal and hepatic. CONCLUSIONS AND CLINICAL IMPORTANCE: The combination of hypofractionated RT, toceranib, and prednisone was tolerated and efficacious in the majority of dogs. Response rates and durations were higher than those reported for toceranib as a single-agent treatment for MCT. This combination is a viable treatment option for unresectable MCT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.